VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physicians combat cancer's most resistant forms. Targeted therapies and immunotherapies are increasingly offering viable alternatives to chemotherapies that have stood for decades as treatment mainstays[2], replacing blunt cytotoxic approaches with precision mechanisms that attack cancer cells while preserving healthy tissue. This pivot toward precision efficacy drives the investment thesis for GT Biopharma, Inc. (NASDAQ:GTBP), Lyell Immunopharma, Inc. (NASDAQ:

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has signaled smart money abandoning single-asset risk for companies engineering multiple drugs from validated mechanisms[1]. Antibody-drug conjugate pipelines expanding past 200 clinical candidates demonstrate how platform technologies enable rapid target-swapping while preserving core therapeutic advantages, creating sustainable competitive moats that command premium valuations[2]. This structural shift toward modularity positions companies with proprietary engines to capture multiple therapeutic opportunit

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – The recent FDA approval in November of the first bispecific antibody combination for second-line blood cancer treatment marks the departure from traditional chemotherapy that oncologists have been anticipating for decades[1]. Engineered cell therapies and bispecific antibodies are now achieving response rates exceeding 90% in patients with relapsed and refractory hematologic malignancies, demonstrating the transformative power of immunotherapy in blood cancers[2]. These breakthroughs position companies like GT Biopharma, Inc. (NASDAQ:GTBP), Regeneron Pharmaceuticals, Inc. (NAS

VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief – The market is repricing risk around a single variable: detection. The most dangerous threats are the ones that cannot be seen. Hidden cardiac defects collapsing athletes. Tumors camouflaged in healthy tissue. Mineral deposits buried beneath overburden. The asymmetry is total. The defender is blind. The threat is invisible. This is the new arbitrage. While capital chases AI efficiency and margin expansion, a parallel trade is emerging. The companies engineering visibility where none existed before. The thesis is simple. In a world where the unseen becomes lethal, the ability to de

Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer drug revenues, reflecting investor confidence in technologies that engineer specific biological outcomes[2]. Companies deploying proprietary platforms to target previously undruggable proteins are capturing premium valuations as the sector pivots toward modularity and rapid reuse of validated mechanisms, creating momentum for GT Biopharma, Inc.

Issued on behalf of Quantum Security Encryption Corp. VANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) -- EquityInsider.com Market Intelligence Brief The capital rotation is underway. After years of speculative excess, the market is exhausted by "potential". Investors have shifted from narrative to numbers, rewarding tangible assets and verifiable proof. This isn't a retreat from risk; it's a flight to execution. The winners share one trait: They aren't selling dreams. They are building factories. THE MONETARY ANCHOR Lake Victoria Gold (TSXV:LVG) (OTCQB:LVGLF) operates at the intersection of historic opportunity and tactical location. Gold is trading at all-time highs. Th

Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

Phase 1 trial evaluating GTB-3650 TriKE® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE® IND submission for B7H3-expressing solid tumors expected in late December 2025 or January 2026 SAN FRANCISCO, CALIFORNIA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced third quarter 2025 financial results for the period ended September 30, 2025. The Company's Phase

The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening patients for Cohort 4; anticipate initiation of dosing in the coming weeks Cohort 4 dose is potentially more reflective of the clinical efficacy threshold given positive trend in observations on multiple immunological biomarkers from the previous six patients in Cohorts 1 through 3, the absence of dose limiting toxicities, and the associated lower dose levels Next update expected in Q1 2026, as well as continued dose escalation (up to 100ug/kg/day) in 3 additional cohorts if neces

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

4 - GT Biopharma, Inc. (0000109657) (Issuer)

4 - GT Biopharma, Inc. (0000109657) (Issuer)

4 - GT Biopharma, Inc. (0000109657) (Issuer)

4 - GT Biopharma, Inc. (0000109657) (Issuer)

4 - GT Biopharma, Inc. (0000109657) (Issuer)

3 - GT Biopharma, Inc. (0000109657) (Issuer)

3 - GT Biopharma, Inc. (0000109657) (Issuer)

3 - GT Biopharma, Inc. (0000109657) (Issuer)

4 - GT Biopharma, Inc. (0000109657) (Issuer)

3 - GT Biopharma, Inc. (0000109657) (Issuer)

EFFECT - GT Biopharma, Inc. (0000109657) (Filer)

424B3 - GT Biopharma, Inc. (0000109657) (Filer)

8-K - GT Biopharma, Inc. (0000109657) (Filer)

10-Q - GT Biopharma, Inc. (0000109657) (Filer)

8-K - GT Biopharma, Inc. (0000109657) (Filer)

S-1 - GT Biopharma, Inc. (0000109657) (Filer)

8-K - GT Biopharma, Inc. (0000109657) (Filer)

8-K - GT Biopharma, Inc. (0000109657) (Filer)

8-K - GT Biopharma, Inc. (0000109657) (Filer)

8-K - GT Biopharma, Inc. (0000109657) (Filer)

ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00

HC Wainwright & Co. initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00

B. Riley Securities initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $21.00

ROTH Capital initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00

Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors. "We are very pleased to welcome David to the Board of Directors. David is an experienced senior executive with global connections and a proven track record of success in working with corporate management teams," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. "His guidance and perspective will be

SAN FRANCISCO, CALIFORNIA, May 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of Hilary Kramer to its Board of Directors. Mrs. Kramer will be replacing current board member Bruce Wendel, who is resigning his position. "We are delighted to welcome Hilary to the Board of Directors at this exciting time, and we look forward to leveraging her expertise as we continue to make great clinical progress with our NK engagers," said Michael Breen, Executive Chairman a

BRISBANE, Calif., Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced the appointment of Manu Ohri, who joins the Company as its Chief Financial Officer (CFO) effective immediately. Mr. Ohri, an accomplished accounting and finance executive brings to GT Biopharma over 25 years of management, finance and public accounting experience in working with Boar

BEVERLY HILLS, Calif., Nov. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary Tri-specific natural killer (NK) cell engager, TriKE® platform, today announced a restructuring of its executive management team. Mr. Anthony Cataldo, Chairman and Chief Executive Officer and Mr. Michael Handelman, Chief Financial Officer will both pursue other interests. The Board has appointed Dr. Gregory Berk as interim CEO, and Dr. Gavin Choy as acting CFO. Michael Breen has assumed the role of Executive Chairman of the Board, Chair of the Audit Committee and will ove

BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the position of Chief Medical Officer. Dr. Berk has served as a Director on GT Biopharma's Board since November 2020, and resigns that post in conjunction with his appointment. The Company is also pleased to announce that Jeffrey S. Mi

SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

SC 13G - GT Biopharma, Inc. (0000109657) (Subject)

SC 13G - GT Biopharma, Inc. (0000109657) (Subject)

SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell

Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions' Share Price Has Declined More than 20% THOUSAND OAKS, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Peter Derycz, Bristol Investment Fund Ltd. ("Bristol Fund") and certain of Bristol Fund's affiliates (collectively, the "Group"), who collectively beneficially own approximately 20% of Research Solutions, Inc.'s (NASDAQ:RSSS) outstanding shares, today issued an open letter from Mr. Derycz to RSSS shareholders regarding why change is needed at RSSS and the Group's intention t

BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference call on Tuesday, November 30th at 4:30PM Eastern Time. To join the live webcast of the call and view the accom

BEVERLY HILLS, Calif., Aug. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE®) protein biologic technology platform, today provided a general business update of events in the second quarter ending June 30, 2021. "I am pleased with the corporate and clinical development milestones that GT Biopharma continues to achieve throughout the first half of 2021," said Anthony J. Catal

BEVERLY HILLS, Calif., Aug. 6, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that the management team will host a conference call to discuss second quarter 2021 financial results and general business updates on August 13, 2021 at 8:30 a.m. EST. To join the call: U.S. callers should dial 1-877-870-4263 and international